# DILLICO

> Dillico builds continuous mRNA-LNP manufacturing equipment and services, enabling scale from early development to commercial production on a single GMP-ready platform.

Dillico is an mRNA manufacturing biotech headquartered in Grenoble, France. Our flagship technology, All-ScaleFlow™, integrates in-vitro transcription (IVT), purification, and lipid nanoparticle (LNP) formulation into one automated, meso-fluidic workflow. Our mRNAfacturing™ approach combines proven GMP components, semi-continuous reaction, and a Process Performance Modeling Platform to deliver continuous manufacturing without reinventing GMP.

## Pages

- [Home](/): Overview of Dillico and All-ScaleFlow™ continuous mRNA-LNP manufacturing.
- [mRNAfacturing™ Approach](/mrnafacturing-approach): Our three-pillar approach to continuous mRNA-LNP manufacturing with high GMP readiness.
- [All-ScaleFlow™ Equipment](/all-scaleflow): The integrated end-to-end continuous manufacturing equipment for mRNA synthesis, purification, and LNP formulation.
- [Get Started](/get-started): Evidence Package service — feasibility to validation for your mRNA-LNP process in about 3 months.
- [Events & News](/events-news): Dillico conferences, announcements, and press releases.
- [About](/about): Team, founders, mission, and Grenoble roots.

## Optional

- [Privacy Policy](/privacy-policy)
- [Legal Mentions](/legal-mentions)